{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.07","value":"57.4"},{"groupId":"OG001","spread":"2.26","value":"59.1"}]}],"title":"6 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.24","value":"50.7"},{"groupId":"OG001","spread":"3.12","value":"53.3"}]}],"title":"12 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.74","value":"46.2"},{"groupId":"OG001","spread":"3.49","value":"43.8"}]}],"title":"24 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.96","value":"42.3"},{"groupId":"OG001","spread":"3.65","value":"34.2"}]}],"title":"48 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.12","value":"37.0"},{"groupId":"OG001","spread":"3.77","value":"26.1"}]}],"title":"72 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.75","value":"31.3"},{"groupId":"OG001","spread":"3.49","value":"23.4"}]}],"title":"4 days post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.11","value":"29.0"},{"groupId":"OG001","spread":"3.76","value":"21.6"}]}],"title":"5 days post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.04","value":"28.1"},{"groupId":"OG001","spread":"3.71","value":"20.5"}]}],"title":"6 days post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.03","value":"24.1"},{"groupId":"OG001","spread":"3.70","value":"19.1"}]}],"title":"7 days post-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"description":"Patient's assessment of gout pain intensity in the most affected joint (on a 0-100 mm VAS) for the last post-baseline flare, ranging from no pain (0) to unbearable pain (100), was summarized up to 7 days after receiving a re-dose of study drug by time point. Scores on the 100 mm linear scale were measured to the nearest millimeter from the left. The covariance analysis included treatment group, Baseline VAS score at that flare, and body mass index (BMI) at Baseline as covariates.","dispersionType":"Standard Error","groups":[{"description":"Participants received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. In the first extension study participants completing the 12 week core study could continue to be treated on demand with the same treatment for another 12 weeks for any new gout flare.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Participants received 1 intramuscular injection of triamcinolone acetonide 40 mg and 1 sc injection of placebo to canakinumab on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose.\n\nIn the first extension study participants completing the 12 week core study could continue to be treated on demand with the same treatment for another 12 weeks for any new gout flare.","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set (FAS) consisted of all patients as randomized in the core study who had taken at least one dose of study drug. For assessments made up to 7 days after re-dosing, pain values were imputed using the Last- Observation-Carried-Forward (LOCF) method.","reportingStatus":"POSTED","timeFrame":"6, 12, 24, 48, and 72 hours; and 4, 5, 6, and 7 days post-dose for last post-baseline flare that occurred up until the end of the first extension study (24 weeks).","title":"Self-assessed Pain Intensity in the Joint Most Affected at Last Post-Baseline Measured on a Visual Analog Scale (VAS)","type":"SECONDARY","unitOfMeasure":"mm"}